Kymera Therapeutics, Inc.
NASDAQ:KYMRBiotechnology
+$1.50 today
- Market cap
- $10.19B
- Beta
- 2.03
- P/E (TTM)
- -28.3
- EPS (TTM)
- -$3.23
Volume 0.72M
Average 0.58M
Returns on capital
Kymera Therapeutics, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-19.7%
avg -4.4%
ROIC
-20.9%
avg -30.9%
ROA
-17.9%
avg -25.2%
Analysis
ROA is currently the strongest return metric at -17.9% versus its period average of -25.2%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Nello Mainolfi | Co-Founder, President, Chief Executive Officer & Director | USD 1.23M | 47 | 60.00K | 0.07% |
Jeremy G. Chadwick | Advisor | USD 806.34K | 63 | 44.02K | 0.05% |
Jared A. Gollob | Advisor | USD 806.34K | 61 | — | — |
Bruce N. Jacobs | Chief Financial Officer | USD 795.25K | — | 0 | <0.01% |
Noah Goodman | Chief Business Officer | USD 597.29K | 39 | 47.18K | 0.06% |
Brian R. Adams | Chief Legal Officer & Corporate Secretary | USD 540.1K | 52 | — | — |
Neil Graham MBBS | Chief Development Officer | — | 67 | — | — |
Brian Albarran | SVP of Corporate Strategy | — | — | — | — |
Justine E. Koenigsberg | Vice President of Investor Relations | — | — | — | — |
Juliet Williams | Head of Research | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Oct 1, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
171
$399.34M
Net Transaction Value
−$399.34M
Net selling
Most Active
Booth Bruce
137 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Oct 1, 26Oct 1, 2026 | Mainolfi Nello Direct | Sell | $869.8K$869,782.43 |
| Oct 1, 26Oct 1, 2026 | Mainolfi Nello Direct | Sell | $30.4K$30,423.44 |
| Oct 1, 26Oct 1, 2026 | Mainolfi Nello Direct | Sell | $552.2K$552,158.24 |
| Oct 1, 26Oct 1, 2026 | Mainolfi Nello Direct | Sell | $392.8K$392,826.00 |
| Oct 1, 26Oct 1, 2026 | Mainolfi Nello Direct | Sell | $619K$618,984.52 |
| Oct 1, 26Oct 1, 2026 | Mainolfi Nello Direct | Sell | $949.7K$949,742.00 |
| Sep 4, 26Sep 4, 2026 | Adams Brian Direct | Sell | $353.4K$353,350.25 |
| Sep 4, 26Sep 4, 2026 | Adams Brian Direct | Sell | $251.2K$251,247.09 |
| Sep 4, 26Sep 4, 2026 | Adams Brian Direct | Sell | $139.7K$139,699.95 |
| Jul 7, 26Jul 7, 2026 | Mainolfi Nello Direct | Sell | $6M$5,950,000.00 |
1–10 of 171
Summary
Insiders reported 0 buys worth $0.00 and 171 sells worth $399.34M over the last 12 months. That adds up to net selling of $399.34M. Booth Bruce was the most active insider with 137 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A13 analysts |
| Revenue | N/A | N/A | -5.8% | +54.4% (5yr)10 analysts |
| Net Income | N/A | N/A | N/A | N/A10 analysts |
| EBIT | N/A | N/A | N/A | N/A10 analysts |
Analysis
Recent growth has been strongest in Revenue at -5.8% over three years. Forward estimates point to Revenue at +54.4% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Who does Kymera Therapeutics, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about KYMR's management, answered from reported figures.
Who manages KYMR?
Kymera Therapeutics, Inc. (KYMR) lists 10 active executives. The top listed executive is Jeremy G. Chadwick, Advisor.
Are KYMR insiders buying or selling?
Recent insider activity shows net selling of $385.46M.
Continue the stock analysis
Jump to another research area for this company.